- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
- Interventions
- peripheral blood lymphocyte therapy
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 1 Year to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 598
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study, dexamethasone
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more
- Conditions
- Eczema, MTOROC1 Signaling
- Interventions
- L-glutamine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- ALIS, Azithromycin, Ethambutol, ELC
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Fresno, California • San Diego, California + 24 more
- Conditions
- Cancer
- Interventions
- recombinant adenovirus-hIFN-beta
- Biological
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Pain
- Interventions
- Hydrocodone ER
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 54
- States / cities
- Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more
- Conditions
- HIV Infections
- Interventions
- Nevirapine, Zidovudine
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 18
- States / cities
- San Diego, California • San Francisco, California • Wilmington, Delaware + 15 more
- Conditions
- MAC Lung Disease, Treatment Refractory MAC Lung Disease
- Interventions
- Epetraborole, Placebo
- Drug
- Lead sponsor
- AN2 Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more
- Conditions
- Mesothelioma, Pleural Mesothelioma, Wilms Tumor
- Interventions
- Galinpepimut-S, Nivolumab, Sargramostim
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Thymic Carcinoma
- Interventions
- Milciclib Maleate
- Drug
- Lead sponsor
- Tiziana Life Sciences LTD
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- Interleukin-12
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2001
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
- Conditions
- Psychosocial Circumstances
- Interventions
- Seminar and Practicum
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Not listed
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm
- Interventions
- LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab
- Combination Product
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 4
- States / cities
- Long Beach, California • Sacramento, California • San Francisco, California + 1 more
- Conditions
- HIV Infections
- Interventions
- HBY 097, Zidovudine
- Drug
- Lead sponsor
- Hoechst Marion Roussel
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
- Interventions
- Everolimus, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 8 more
- Conditions
- Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder, REM Sleep Measurement, Insomnia, Insomnia Related to Specified Disorder, Insomnia Due to Other Mental Disorder, Insomnia Comorbid to Psychiatric Disorder, Insomnia Due to Anxiety and Fear, Insomnia Related to Another Mental Condition, Insomnia Disorders, Idiopathic Hypersomnia, Sleep Disorders, Circadian Rhythm, Post Trauma Nightmares, PTSD - Post Traumatic Stress Disorder, Sleep Quality, Anesthesia, Anxiety, Depression, Mental Health, Alzheimer Disease or Associated Disorder, Parkinsons, Circadian Rhythm, Circadian Dysregulation, PTSD, Post-Traumatic, Post-Traumatic Stress Disorder Complex, Military Combat Stress Reaction, Sleep, Military Activity, Veterans, Shift Work Sleep Disorder, Menopause Related Conditions, Pain, Cancer Pain, Athletes
- Interventions
- PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca, Continuous EEG Monitoring
- Procedure · Drug · Device
- Lead sponsor
- Nyree Penn
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Aventura, Florida
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Thymic Carcinoma
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 15
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 11 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Pentamidine isethionate, Dapsone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1994
- U.S. locations
- 14
- States / cities
- San Francisco, California • Denver, Colorado • Wilmington, Delaware + 10 more
- Conditions
- Mycobacterium Avium-Intracellulare Infection, HIV Infections
- Interventions
- Rifabutin
- Drug
- Lead sponsor
- Pharmacia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Harbor City, California • Irvine, California + 17 more
- Conditions
- HIV Infections
- Interventions
- Interferon alfa-n3
- Drug
- Lead sponsor
- Interferon Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension, Anxiety, Atrial Fibrillation, Congestive Heart Failure, Depression, Bipolar Disorder, Schizophrenia
- Interventions
- High-Touch, High-Tech, Optimal Discharge Planning
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Reversal of Anticoagulant Treatment
- Interventions
- Octaplex (human prothrombin complex concentrate), Fresh frozen plasma
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma
- Interventions
- Cediranib Maleate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 11
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- HIV Infections
- Interventions
- Dextran sulfate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more